About
StoryLeadershipVideo LibraryContactProducts
Explore PlasmaDriveHead-to-head comparisonThe EvidenceMobility IndexBrowse all productsHydraDrive — coming soonGutDrive — coming soonPartnershipsJoin the Founding PackCompetitive analysis
A head-to-head look at PlasmaDrive against four leading canine joint formulas - on the levers that matter: how many inflammatory and structural pathways each one covers, how many actives it actually discloses, and whether the label hides anything.
Build your own comparison
Pick the product you’re weighing PlasmaDrive against. You’ll see how the two stack up on mechanism coverage, disclosed actives, and label transparency — no chart-reading required. Purchase cost is in the table below.
At 70 lb, label-directed dosing. Pathway coverage reflects published label actives and their established mechanisms — not a claim of clinical equivalence or superiority. Structure/function only; no ingredient is intended to diagnose, treat, cure, or prevent any disease. Product names are trademarks of their respective owners, used for identification only.
What you actually pay to start
The cash you hand over for enough product to cover a 30-day supply at each label’s initial dose — not the value consumed. On the shelf, the cheapest price per container isn’t always the cheapest month.
| Product | Chews/day | 30-day need | Containers | Initial cost |
|---|---|---|---|---|
| Phoenix PlasmaDrive™ | 2 | 60 | 1 jar (60) | $64.99 |
| WINPRO Hip & Joint | 3 | 90 | 2 jars (60 ea.) | $57.99* |
| Jope Hip & Joint | 2 | 60 | 1 jar (60) | $62.93 |
| Dasuquin with MSM | 2 initial | 60 | 1 bottle (84) | $59.99 |
Based on each label’s initial dosing for a 70 lb dog and a 30-day supply. Initial purchase cost is the cash paid for enough containers, not the value consumed. * WINPRO reflects a previously identified two-container bundle price; confirm offer at publication. Prices are indicative and must be rechecked against current retailer/manufacturer listings. Shipping, taxes, discounts, subscriptions, and promotional pricing are excluded. Dasuquin is shown at its initial dosage; maintenance recommendations may differ.
Where each product acts on osteoarthritis
Osteoarthritis is cartilage loss running ahead of repair — driven by inflammatory signaling, enzymatic breakdown and immune activity, with pain and joint-fluid changes on top. A formula is only as complete as the number of those points it touches.
| Pathway in the arthritic joint | PlasmaDrive active | PlasmaDrive | WINPRO | Jope | Dasuquin Adv. | Dasuquin MSM | Cosequin Max |
|---|---|---|---|---|---|---|---|
| Cytokine & NF-κB inflammatory signaling | Porcine plasma 2,500 mg + ASU | ● | ● | ◐ | ◐ | ◐ | — |
| Immune attack on joint cartilage oral tolerance | UC-II® 20 mg (40 mg/day at 2 chews) | ● | — | ● | — | — | — |
| 5-LOX / leukotriene pathway stiffness | Boswellia 65% AKBA 200 mg | ● | — | — | ● | ● | — |
| Prostaglandin load & inflammatory resolution | Fish oil 200 mg + green-lipped mussel 150 mg | ● | — | ● | ● | — | ◐ |
| Chondrocyte anabolism & matrix synthesis | ASU 45 mg | ● | ◐ | — | ● | ● | ● |
| Cartilage-degrading enzyme inhibition MMP & aggrecanase | ASU with plasma protein support | ● | — | — | ● | ● | ◐ |
| Pain signaling & mast-cell activity comfort | Ultra-micronized PEA 150 mg | ● | — | — | — | — | — |
| Synovial fluid viscosity & lubrication | Hyaluronic acid 20 mg | ● | — | — | — | — | — |
| Bone & musculoskeletal support | Vitamin D3 375 IU | ● | — | — | — | — | — |
| Pathways covered | 9 | 2 | 3 | 5 | 4 | 2 |
● full · ◐ partial or sub-clinical dose · — none
Actives on the label vs. actives you can verify
Dasuquin Advanced carries ten actives to our nine. It carries none of the four that define PlasmaDrive — plasma, UC-II, PEA, and hyaluronic acid.
| Product | Actives | What’s in it | What it does not have | Per-ingredient mg |
|---|---|---|---|---|
| PlasmaDrive™ | 9 | Plasma 2,500 mg, boswellia 200 mg, fish oil 200 mg, PEA 150 mg, green-lipped mussel 150 mg, ASU 45 mg, UC-II® 20 mg, HA 20 mg, D3 375 IU | Glucosamine & chondroitin, by design | Full panel |
| WINPRO Hip & Joint | 2 | A proprietary porcine plasma blend and collagen blend | UC-II, PEA, ASU, boswellia, omega-3, GLM, HA, D3 | None |
| Jope Hip & Joint | 3 | UC-II® 20 mg, fish oil 200 mg (98 mg EPA+DHA), curcumin 50 mg | Plasma, ASU, PEA, boswellia, GLM, HA, D3 | Full panel |
| Dasuquin Advanced, large | 10 | Glucosamine, chondroitin, ASU, boswellia, green tea, MSM, turmeric, alpha-lipoic acid, manganese, omega-3 | Plasma, UC-II, PEA, HA | Full panel |
| Dasuquin with MSM, large | 6 | Glucosamine, chondroitin, ASU, MSM, boswellia, green tea | Plasma, UC-II, PEA, HA, omega-3, D3 | Full panel |
| Cosequin Maximum Strength | 4 | Glucosamine 600 mg, MSM 400 mg, chondroitin 300 mg, omega-3 70 mg | Plasma, UC-II, PEA, ASU, boswellia, GLM, HA, D3 | Full panel |
Competitor pricing and label dosing verified 14 September 2026 from manufacturer sites and Chewy list pricing; Dasuquin Advanced is veterinarian-exclusive and clinic pricing varies. Dosing per each manufacturer’s published directions at 70 lb. Maintenance-tier costs assume the label’s lowest maintenance amount and are not like-for-like with a full-dose product. Pathway coverage reflects published label actives and their established mechanisms; it is not a claim of clinical equivalence or superiority. All statements are structure and function; no ingredient is intended to diagnose, treat, cure, or prevent any disease. Product names are trademarks of their respective owners, used for identification only.
Comparison compiled from publicly available product labels and manufacturer materials. PlasmaDrive is a Phoenix Bioscience formula. Other product names are trademarks of their respective owners and are used for identification only.